Manila Times Business
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
1h ago
Telesat announces results of 2026 Annual General Meeting of shareholders
1h ago
TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology
1h ago
Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets
1h ago